PDF(Pubmed)
Abstract：
UNASSIGNED: Chronic spontaneous urticaria (CSU) is defined as the spontaneous occurrence of hives, angioedema, or both for more than 6 weeks; several inciting triggers including vaccines have been implicated. Coronavirus disease 2019 (COVID-19) vaccinations have been well tolerated by patients with CSU. However, reports have emerged of CSU triggered by COVID-19 vaccination and this study describes a South African case series.
UNASSIGNED: To provide details of the first case series of new-onset CSU post-COVID-19 vaccination in Africa and summarize the global literature of reported cases to date.
UNASSIGNED: All patients referred to our Urticaria Center of Excellence in Cape Town from the initiation of the COVID-19 vaccine rollout in South Africa (from February 2021 to August 2022) were reviewed to identify patients who developed new-onset CSU within 12 weeks of receiving a COVID-19 vaccine. Medical history, physical examinations, and laboratory investigations were reviewed.
UNASSIGNED: More than 20 million adults received COVID-19 vaccinations in South Africa during the study period. Eight patients had new-onset chronic urticaria post-COVID-19 vaccination; 6 of the 8 patients were female, the median age was 41 years (interquartile range [IQR], 38-44), and all had a history of atopy. Only 1 reported COVID-19 infection post vaccination. Chronic urticaria occurred following Pfizer-BioNTech, AstraZeneca, and Janssen Ad26.COV2.S vaccination in 6, 1, and 1 patient, respectively, with a median of 12 days (IQR, 3-38) from vaccination to symptoms onset. The baseline median score for Urticarial Activity Score 7 was 34 (IQR, 29-40), and 5 of the 8 patients (63%) had a total IgE level of more than 43 IU/L. All patients received high-dose antihistamines, with only 3 patients controlled.
UNASSIGNED: New-onset CSU can rarely be triggered by COVID-19 vaccinations, most commonly mRNA vaccines. COVID-19 vaccine-triggered CSU appears to have a phenotype similar to that triggered by other inciting agents and across populations.
UNASSIGNED: To provide details of the first case series of new-onset CSU post-COVID-19 vaccination in Africa and summarize the global literature of reported cases to date.
UNASSIGNED: All patients referred to our Urticaria Center of Excellence in Cape Town from the initiation of the COVID-19 vaccine rollout in South Africa (from February 2021 to August 2022) were reviewed to identify patients who developed new-onset CSU within 12 weeks of receiving a COVID-19 vaccine. Medical history, physical examinations, and laboratory investigations were reviewed.
UNASSIGNED: More than 20 million adults received COVID-19 vaccinations in South Africa during the study period. Eight patients had new-onset chronic urticaria post-COVID-19 vaccination; 6 of the 8 patients were female, the median age was 41 years (interquartile range [IQR], 38-44), and all had a history of atopy. Only 1 reported COVID-19 infection post vaccination. Chronic urticaria occurred following Pfizer-BioNTech, AstraZeneca, and Janssen Ad26.COV2.S vaccination in 6, 1, and 1 patient, respectively, with a median of 12 days (IQR, 3-38) from vaccination to symptoms onset. The baseline median score for Urticarial Activity Score 7 was 34 (IQR, 29-40), and 5 of the 8 patients (63%) had a total IgE level of more than 43 IU/L. All patients received high-dose antihistamines, with only 3 patients controlled.
UNASSIGNED: New-onset CSU can rarely be triggered by COVID-19 vaccinations, most commonly mRNA vaccines. COVID-19 vaccine-triggered CSU appears to have a phenotype similar to that triggered by other inciting agents and across populations.
摘要：
■慢性自发性荨麻疹（CSU）定义为荨麻疹的自发发生，血管性水肿,或两者都超过6周；涉及包括疫苗在内的一些煽动性触发因素。CSU患者对2019年冠状病毒病（COVID-19）疫苗接种的耐受性良好。然而,已经出现了由COVID-19疫苗引发的CSU的报告，这项研究描述了南非的一个病例系列。
提供非洲第一例COVID-19疫苗接种后新发CSU病例系列的详细信息，并总结迄今为止报告病例的全球文献。
从COVID-19疫苗在南非推出开始（2021年2月至2022年8月）到开普敦荨麻疹卓越中心的所有患者都进行了审查，以确定在接受COVID-19疫苗后12周内开发出新发CSU的患者。病史,体检,和实验室调查进行了审查。
■在研究期间，南非有超过2000万成年人接受了COVID-19疫苗接种。8例患者在COVID-19疫苗接种后出现新发慢性荨麻疹，其中6例为女性，中位年龄为41岁(四分位距[IQR]，38-44),都有过特应症的历史。只有1人报告了疫苗接种后的COVID-19感染。Pfizer-BioNTech后发生慢性荨麻疹，阿斯利康，和JanssenAd26。COV2.6、1和1名患者的S疫苗接种，分别,中位数为12天(IQR，3-38）从疫苗接种到症状发作。荨麻疹活动评分7的基线中位数为34分(IQR，29-40),8例患者中有5例（63％）的总IgE水平超过43IU/L。所有患者都接受了高剂量抗组胺药,只有3名患者得到控制。
■新发CSU很少可以由COVID-19疫苗引发，最常见的mRNA疫苗。COVID-19疫苗触发的CSU似乎具有与其他煽动剂和跨人群触发的表型相似的表型。
提供非洲第一例COVID-19疫苗接种后新发CSU病例系列的详细信息，并总结迄今为止报告病例的全球文献。
从COVID-19疫苗在南非推出开始（2021年2月至2022年8月）到开普敦荨麻疹卓越中心的所有患者都进行了审查，以确定在接受COVID-19疫苗后12周内开发出新发CSU的患者。病史,体检,和实验室调查进行了审查。
■在研究期间，南非有超过2000万成年人接受了COVID-19疫苗接种。8例患者在COVID-19疫苗接种后出现新发慢性荨麻疹，其中6例为女性，中位年龄为41岁(四分位距[IQR]，38-44),都有过特应症的历史。只有1人报告了疫苗接种后的COVID-19感染。Pfizer-BioNTech后发生慢性荨麻疹，阿斯利康，和JanssenAd26。COV2.6、1和1名患者的S疫苗接种，分别,中位数为12天(IQR，3-38）从疫苗接种到症状发作。荨麻疹活动评分7的基线中位数为34分(IQR，29-40),8例患者中有5例（63％）的总IgE水平超过43IU/L。所有患者都接受了高剂量抗组胺药,只有3名患者得到控制。
■新发CSU很少可以由COVID-19疫苗引发，最常见的mRNA疫苗。COVID-19疫苗触发的CSU似乎具有与其他煽动剂和跨人群触发的表型相似的表型。
